Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss

The differentiation shift from osteogenesis to adipogenesis of bone marrow mesenchymal stem cells (BMSCs) characterizes many pathological bone loss conditions. Stromal cell-derived factor-1 (SDF1) is highly enriched in the bone marrow for C-X-C motif chemokine receptor 4 (CXCR4)-positive hematopoietic stem cell (HSC) homing and tumor bone metastasis. In this study, we displayed CXCR4 on the surface of exosomes derived from genetically engineered NIH-3T3 cells. CXCR4(+) exosomes selectively accumulated in the bone marrow. Then, we fused CXCR4(+) exosomes with liposomes carrying antagomir-188 to produce hybrid nanoparticles (NPs). The hybrid NPs specifically gathered in the bone marrow and released antagomir-188, which promoted osteogenesis and inhibited adipogenesis of BMSCs and thereby reversed age-related trabecular bone loss and decreased cortical bone porosity in mice. Taken together, this study presents a novel way to obtain bone-targeted exosomes via surface display of CXCR4 and a promising anabolic therapeutic approach for age-related bone loss.

Automated summary

This study demonstrates a novel approach to target bone marrow through surface display of CXCR4 on exosomes, which are then fused with liposomes carrying antagomir-188 to produce hybrid nanoparticles. These nanoparticles selectively accumulate in bone marrow, release antagomir-188, promote osteogenesis, inhibit adipogenesis, and reverse bone loss conditions, presenting a promising therapeutic strategy for age-related bone loss.